Manuela Corti
Co-founder
AI
AavantiBio, Inc.
aavantibio.com
Website unreachable since Oct 19, 2026
AavantiBio develops gene transfer and gene editing therapies to treat genetic diseases caused by specific genetic mutations. Their approach aims to restore normal gene function, providing patients with potential long-term solutions to previously untreatable conditions.
- Biotechnology
Updated 5 months ago
Funding
Raised to date
$107MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Barry Byrne
Co-founder
Product
Problem
Many genetic diseases lack effective treatments because they are caused by specific mutations that disrupt normal gene function. These conditions often have limited therapeutic options, leaving patients with significant unmet medical needs.
Solution
AavantiBio is developing gene transfer and gene editing therapies designed to address the underlying genetic causes of inherited diseases. Their approach focuses on delivering functional genes or correcting mutated genes within a patient's cells, with the goal of restoring normal gene function and providing long-term therapeutic benefits. By targeting the root cause of these diseases, AavantiBio aims to offer potentially curative treatments for conditions that currently have limited or no effective therapies.
Target Audience
The primary target audience includes patients diagnosed with specific genetic diseases caused by defined genetic mutations, as well as their families and healthcare providers.
Features
- Gene transfer therapies utilizing viral vectors to deliver functional genes to target cells.
- Gene editing technologies designed to correct specific disease-causing mutations within the genome.
- Development of therapies for genetic diseases caused by specific genetic mutations.
- Focus on restoring normal gene function to address the underlying cause of disease.